Intellia Data from Ongoing Phase 1 Study of NTLA-2001 for Transthyretin (ATTR) Amyloidosis

 

• New interim NTLA-2001 clinical data to be presented at the 4^th International ATTR Amyloidosis Meeting on November 2; data to include safety and both absolute and percent change in serum TTR reduction from cardiomyopathy and polyneuropathy arms of the study
• Intellia management to discuss latest NTLA-2001 data and share additional information about the upcoming Phase 3 study design at Q3 earnings webcast on November 9 at 8 a.m. ET    

• Presentation Details:
  • Title: "Enabling the Development of Serum TTR as a Biomarker for Treatment of ATTR Amyloidosis”
  • Date and Time: Thursday, November 2, 2023, from 11:30 a.m. – 1:00 p.m. CET
  • Session: Latest Data for Patients’ Diagnosis in a Changing World
  • Presenter: Dr. Julian Gillmore, M.D, Ph.D., FRCP, FRCPath, Professor of Medicine, National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, U.K., the trial’s U.K. national coordinating investigator

Third Quarter 2023 Earnings
Intellia will host a webcast to discuss its third quarter 2023 financial results and operational highlights on November 9, 2023, at 8 a.m. ET. The Company will also review the NTLA-2001 data presented at the 4^th International ATTR Amyloidosis Meeting.

• To join the webcast, please visit this link, or the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com.
• A replay of the call will be available beginning on November 9, 2023, at 12 p.m. ET.

https://www.biospace.com/article/releases/intellia-therapeutics-to-present-updated-data-from-ongoing-phase-1-study-of-ntla-2001-for-the-treatment-of-transthyretin-attr-amyloidosis-and-hold-conference-call-to-discuss-third-quarter-2023-earnings-in-november/